ClinConnect ClinConnect Logo
Search / Trial NCT05407623

A Cluster-randomized Control Trial of PAX Good Behavior Game in Swedish Elementary Schools

Launched by LINNAEUS UNIVERSITY · Jun 1, 2022

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Prevention Pedagogy Psychology Leadership Pedagogical Leadership Learning Work Related Stress Mental Health Work Environment School Based Research Qualitative Reserach Quantitative Research Good Classroom Environment Math Skills

ClinConnect Summary

This clinical trial is studying the effects of a program called PAX Good Behavior Game in Swedish elementary schools. The main goal is to see how this program can improve the well-being of students and reduce stress among teachers. PAX is designed to be part of regular classroom activities, helping teachers encourage positive behaviors while also providing them with tools to manage stress in their jobs. The study will involve 84 teachers from 28 schools, who will either use the PAX program or participate in a control group with different support. Researchers will measure changes in student health, teacher stress, and academic performance over a year.

To be eligible for this trial, schools must follow the general study plan and have at least one teacher willing to take part. The teacher should be working with 1st or 2nd graders and ready to implement the PAX program. Schools cannot be using other methods that are also aimed at improving the classroom environment at the same time. Participants can expect training on the PAX program and regular assessments to track progress. This study is important as it aims to find effective ways to support both students and teachers in managing mental health and improving the school experience.

Gender

ALL

Eligibility criteria

  • ON SCHOOL LEVEL:
  • Inclusion Criteria:
  • The school uses the general study plan (i.e. the school is not only working with students with special needs)
  • There is at least one teacher that is willing to participate, signs the study consent, and will be able to start the implementation in his/her class at the earliest in the second semester in the first grade or at the latest the first semester in the third grade.
  • The principal has signed an agreement to participate in the project, to allow some time for measurements to be administrated, aid in delivering information to the parents, and that the school are responsible for implementing the methods within their regular operation (given that supervision is provided by the research team)
  • Exclusion Criteria:
  • Another method that specifically aims to improve study and classroom environment is being implemented
  • Another method that is expected to be time and energy consuming for teachers is being implemented during the same period
  • ON TEACHER LEVEL:
  • Inclusion criteria:
  • The teacher mentors a class of 1st or 2nd graders following the general study plan (ready to implement the program no later than the first semester of the 3rd grade) and deems the class suitable for inclusion in the study
  • The teacher has signed the informed consent
  • Exclusion criteria:
  • The teacher has expressed plans to terminate their employment during the upcoming two years
  • A major change in the composition of the class is planned during the upcoming year.

About Linnaeus University

Linnaeus University is a prominent academic institution in Sweden, dedicated to advancing knowledge and innovation through rigorous research and education. As a clinical trial sponsor, the university leverages its interdisciplinary expertise to conduct high-quality research that addresses critical health challenges. With a commitment to ethical standards and participant safety, Linnaeus University fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into practical solutions that enhance patient care and improve health outcomes. Through its clinical trials, the university contributes to the global body of medical knowledge and supports the development of new therapeutic strategies.

Locations

Stockholm, , Sweden

Patients applied

0 patients applied

Trial Officials

Viktor Kaldo, PhD

Principal Investigator

Linnaeus University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials